McKesson to acquire Precision Medicine Group for $2.25 billion
- McKesson (NYSE:MCK) agreed to acquire Precision Medicine Group for approximately $2.25 billion.
- The acquisition expands McKesson’s oncology and multispecialty clinical research and commercialization capabilities.
- Precision Medicine Group will join McKesson’s Oncology & Multispecialty segment after closing.
McKesson (NYSE:MCK) agreed to acquire Precision Medicine Group for approximately $2.25 billion, adding clinical research and biopharma commercialization services to its oncology and multispecialty operations.
Precision Medicine Group provides services for biotechnology and pharmaceutical companies, including biomarker intelligence, laboratory services, global clinical research, market access consulting, and commercialization support.
Following completion of the transaction, Precision Medicine Group will report within McKesson’s Oncology & Multispecialty segment, subject to customary closing conditions including regulatory clearances.
McKesson stated that Precision Medicine Group’s capabilities are expected to expand its clinical research and commercialization services, while Precision Medicine Group said the combination will provide broader support for biopharma customers.
McKesson operates healthcare distribution, technology, and services businesses, while the Precision Medicine Group acquisition expands its presence in oncology services and pharmaceutical development support.
Frequently asked questions
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
